Importantly, the results showed that compared with IgG2a treatments, PD-1 blockade therapies significantly reversed SPHK1- or MTA3-associated immune dysfunctions and enhanced the immune response against tumor cells, as reflected by the frequencies of CD8+ and GZMB+CD8+ T lymphocytes in melanoma. The gene discussed is PDCD1; the disease is melanoma.